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ABSTRACT  
 
Background & Aims: Obesity is a risk factor for pancreatic cancer. In mice, a high-fat diet 
(HFD) and expression of oncogenic KRAS lead to development of invasive pancreatic ductal 
adenocarcinoma (PDAC) by unknown mechanisms. We investigated how oncogenic KRAS 
regulates the expression of fibroblast growth factor 21 (FGF21), a metabolic regulator that 
prevents obesity, and the effects of recombinant human FGF21 (rhFGF21) on pancreatic 
tumorigenesis. 
 
Methods: We performed immunohistochemical analyses of FGF21 levels in human pancreatic 
tissue arrays, comprising 59 PDAC specimens and 45 non-tumor tissues. We also studied mice 
with tamoxifen-inducible expression of oncogenic KRAS in acinar cells (KrasG12D/+ mice) and 
fElasCreERT mice (controls). KrasG12D/+ mice were placed on a HFD or regular chow diet (control) 
and given injections of rhFGF21 or vehicle; pancreata were collected and analyzed by histology, 
immunoblots, quantitative PCR, and immunohistochemistry. We measured markers of 
inflammation in the pancreas, liver, and adipose tissue. Activity of RAS was measured based on 
the amount of bound GTP. 
 
Results: Pancreatic tissues of mice expressed high levels of FGF21 compared with liver. 
FGF21 and its receptor proteins were expressed by acinar cells. Acinar cells that expressed 
KrasG12D/+ had significantly lower expression of Fgf21 mRNA, compared with acinar cells from 
control mice, partly due to downregulation of PPARG expression—a transcription factor that 
activates Fgf21 transcription. Pancreata from KrasG12D/+ mice on a control diet and given 
injections of rhFGF21 had reduced pancreatic inflammation, infiltration by immune cells, and 
acinar-to-ductal metaplasia compared with mice given injections of vehicle. HFD-fed KrasG12D/+ 
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mice given injections of vehicle accumulated abdominal fat, developed extensive inflammation, 
pancreatic cysts, and high-grade pancreatic intraepithelial neoplasias (PanINs); half the mice 
developed PDAC with liver metastases. HFD-fed KrasG12D/+ mice given injections of rhFGF21 
had reduced accumulation of abdominal fat and pancreatic triglycerides, fewer pancreatic cysts, 
reduced systemic and pancreatic markers of inflammation, fewer PanINs, and longer survival—
only about 12% of mice developed PDACs and none of the mice had metastases. Pancreata 
from HFD-fed KrasG12D/+ mice given injections of rhFGF21 had lower levels of active RAS than 
from mice given vehicle. 
 
Conclusions: Normal acinar cells from mice and humans express high levels of FGF21. In 
mice, acinar expression of oncogenic KRAS significantly reduces FGF21 expression. When 
these mice are placed on a HFD, they develop extensive inflammation, pancreatic cysts, 
PanINs, and PDACs, which are reduced by injection of FGF21. FGF21 also reduces the GTP 
binding capacity of RAS. FGF21 might be used in prevention or treatment of pancreatic cancer. 
 
Keywords: gene regulation, FGFR1, KLB, signaling 
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Introduction 
 
Pancreatic cancer is a fatal disease and is predicted to become the second leading cause of 
cancer-related deaths within a decade1. It is widely observed that mutations of KRAS (e.g., 
KRASG12D) are an essential initiating event for pancreatic cancer2. Previous studies have shown 
that mutant Kras, when expressed in pancreatic progenitor cells from the embryonic stage, is 
sufficient to drive PDAC in the Pdx-1Cre;KrasLSL-G12D/+ (KC) mice3. However, human PDAC likely 
originates from somatic mutations in KRAS in acinar cells during adulthood, suggesting that 
mice expressing mutant KRAS in acinar cells after birth may be more clinically relevant. Notably, 
mutant Kras expressed at an endogenous level in adult acinar cells does not, on its own, lead to 
PDAC4, 5, suggesting that an additional challenge is required.  
 
Obesity is a modifiable risk factor for PDAC, and HFD is a major dietary component that drives 
obesity. Recent studies have shown that when fed a HFD, mice expressing an endogenous 
level of KrasG12D/+ in acinar cells developed marked inflammation, PanIN lesions, and invasive 
PDAC leading to lethality with high penetrance6. However, the mechanism underlying the 
cooperation between HFD and oncogenic KRAS remains a major knowledge gap. 
 
The endocrine FGF21 has emerged as a novel metabolic regulator for the maintenance of lipid, 
glucose, and energy homeostasis7, 8. Studies have shown that the liver is one of the major 
sources of endocrine FGF21 under stress conditions9-11. By serving as an endocrine factor, 
FGF21 promotes the clearance of systemic lipids and glucose, while enhancing insulin 
sensitivity, fatty acid oxidation, and energy expenditure without apparent effects on cell 
proliferation and growth7, 12. Therefore, FGF21 has the pharmacological potential to treat 
obesity, diabetes, and meta-inflammation7, 12-14. The effects of endocrine FGF21 are mediated 
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by binding to the transmembrane binary complex of fibroblast growth factors receptor 1 
(FGFR1) and β-Klotho (KLB)15-17. In the pancreas, under wild-type KRAS conditions, FGF21 
acts directly on acinar cells to protect the pancreas from pancreatitis and proteotoxic stress18, 19; 
however, the interaction between pancreatic FGF21 and oncogenic KRAS in pancreatic 
tumorigenesis has not been previously shown. 
 
In the current study, by using mice with conditional knock-in of KrasLSL-G12D/+ under the control of 
a TM-inducible fElasCreERT driver as described6, 20, 21, we report that FGF21, its target receptor 
FGFR1, and its co-receptor KLB were abundantly expressed in normal acinar cells, suggesting 
that acinar cells are both a source and a target of FGF21. The expression of pancreatic FGF21 
was dramatically downregulated, partly through a PPARG-dependent mechanism, upon an 
endogenous level of KrasG12D/+ expression. Remarkably, under chronic HFD challenge, 
administration of rhFGF21, which compensates for the loss of FGF21 in acinar cells, 
significantly suppressed both pancreatic and systemic inflammation, inhibited RAS activation, 
PanIN lesions, tumor incidence, and liver metastasis, as well as extended the survival of 
KrasG12D/+ mice in comparison to those without rhFGF21 treatment. Our results reveal that 
pancreatic FGF21 is downregulated by KRASG12D, which renders the pancreas vulnerable to 
obesogenic HFD challenge, leading to exacerbated inflammation and invasive PDAC, while 
pharmacological FGF21 counteracts the damaging effects of HFD and mitigates this 
vulnerability.  
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Materials and Methods 
Mouse strains  
CreERT-LoxP recombination approaches were used to control gene expression in pancreatic 
acinar cells. KrasLSL-G12D/+ mice, which possess the conditional knock-in of mutant KrasG12D, were 
obtained as described6. fElasCreERT mice, which express TM-regulated Cre recombinase under a 
full-length Elastase promoter specifically in acinar cells, were described previously22. KrasLSL-
G12D/+
 mice and fElasCreERT mice were cross-bred to generate fElasCreERT;KrasLSL-G12D/+ double-
transgenic mice (called KrasG12D/+ after TM)6, 23. Alternatively, Ptf1aCreERT mice24 were crossed 
with KrasLSL-G12D/+ mice to generate Ptf1aCreERT;KrasLSL-G12D/+ mice (called Ptf1aCreERT;KrasG12D/+ 
after TM)25. Trp53LSL-R172H mice26 were crossed with fElasCreERT mice to generate 
fElasCreERT;Trp53LSL-R172H/+ (called Trp53R172H/+ after TM) mice. All animal experiments were 
reviewed and approved by Stony Brook University Institutional IACUC and the University of 
Texas, MD Anderson Cancer Center IACUC. 
Additional experimental details are provided in the Supplementary Information. 
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Results 
 
Pancreatic acinar cells are both a potential source and a target of FGF21 
Previous studies have shown that HFD and KRASG12D cooperate to promote PDAC with high 
penetrance6, suggesting that acinar cells containing mutant KRAS are susceptible to chronic 
HFD challenge. FGF21 is an important regulator of lipid metabolism and elicits anti-obesity 
effects8, 12 while also protecting the pancreas from pancreatitis and metabolic stress18, 19. In 
order to understand the role of FGF21 in the pancreas and pancreatic tumorigenesis, we 
employed the established fElasCreERT and fElasCreERT;KrasLSL-G12D/+ mice6, 23. We first compared 
the pancreatic and hepatic Fgf21 expression in young adult fElasCreERT control mice one week 
post-TM. Pancreatic Fgf21 expression was significantly higher (>80 times) than that of hepatic 
tissue, which is known as the primary source of endocrine FGF21 under stress conditions 
(Figure 1A). This result concurs with a previous report showing that Fgf21 is highly expressed 
in the normal pancreas27. Immunohistochemistry (IHC) and Western blot further confirmed the 
presence of FGF21 in acinar cells (Figure 1B-C). Correspondingly, the expression of pancreatic 
FGF21 receptor, Fgfr1, was significantly higher (>10 times) than that of the liver (Figure 1D-E). 
The expression of FGF21 co-receptor, Klb, was comparable to that of the liver (Figure 1F), 
which is known to express a high level of Klb28, 29.  Western blot (Figure 1G) and IHC (Figure 
1H, open arrow) studies further confirmed the abundant presence of KLB in acinar cells. 
Comparison of Fgf21, Fgfr1, and Klb expression across the liver, pancreas, and adipose tissues 
in 7-month-old fElasCreERT mice after five months of TM induction revealed that pancreatic Fgf21 
expression remained the highest (Figure 1I). Both the pancreas and adipose tissue expressed 
significantly higher levels of Fgfr1 than the liver (Figure 1J). Klb expression levels were 
comparable across all tissues (Figure 1K). Pancreatic Fgf21 expression was stable regardless 
of the age and the duration post TM treatment (Supplementary Figure 1A). All these data 
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reveal that FGF21, FGFR1, and KLB are highly expressed in normal acinar cells, suggesting 
that pancreatic acinar cells are both a source and a target of FGF21.  
 
FGF21 is a downstream target of oncogenic KRASG12D  
To test if FGF21 plays a role in human pancreatic cancer, we performed IHC analysis of FGF21 
in human pancreatic tissue arrays and found that the PDAC specimens (n=59) had substantially 
lower levels of FGF21 than normal human pancreatic tissues (n=45), which exhibited strong 
FGF21 positive staining in acinar cells (Figure 2A-B). FGF21 was also stained positively in 
normal ducts of both the normal human pancreas and PDAC specimens (Supplementary 
Figure 2A, inset). In addition, from the human GEO database 
(https://www.ncbi.nlm.nih.gov/geoprofiles/78912317), FGF21 expression in human PDAC 
tissues dropped significantly in comparison to the paired normal pancreata (n=39 pairs) (Figure 
2C). Furthermore, FGF21 expression in human pancreatic cancer cell lines carrying KRAS 
mutations decreased significantly in comparison to that of normal human pancreatic ductal 
epithelial (HPDE) cells (Figure 2D), suggesting an inverse association between pancreatic 
FGF21 and oncogenic KRAS. 
 
Given that PDAC likely originates from acinar cells with somatic mutations in KRAS occurring 
after birth, we next analyzed the potential changes of FGF21 in the fElasCreERT;KrasLSL-G12D/+ 
mice that express an endogenous level of KrasG12D/+ in nearly 100% acinar cells upon TM 
induction6. A striking decrease of >100 fold in Fgf21 expression was observed in mice five 
months post-TM relative to the age-matched fElasCreERT mice (Figure 2E). IHC analysis 
confirmed the substantially lower levels of FGF21 in the pancreatic tissues of KrasG12D/+ mice 
compared to that of fElasCreERT mice (Supplementary Figure 2B). To determine whether the 
drastic reduction of pancreatic Fgf21 is an early event related to KrasG12D/+ expression, we first 
compared Fgf21 expression in the 40-day-old fElasCreERT control mice one week post-TM to that 
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without TM. No significant differences were observed between the two groups, suggesting that 
neither TM nor Cre recombinase affected Fgf21 expression (Supplementary Figure 2C). We 
then compared Fgf21 expression one week post-TM induction of KrasG12D/+ to that of the age-
matched (40 days old) mice without TM and found that Fgf21 expression was significantly 
reduced upon KrasG12D/+ induction (Figure 2F), suggesting that the downregulation of Fgf21 is 
specific to KrasG12D/+. Notably, this occurred when no obvious alterations of pancreatic histology 
were observed (Figure 2G). 
 
To further confirm our observation that KRASG12D specifically downregulates Fgf21 expression, 
we employed another mouse strain, the Ptf1aCreERT;KrasLSL-G12D/+ mice25. qRT-PCR data showed 
that Fgf21 expression was significantly reduced in these mice two weeks post-TM in 
comparison to the age-matched (two months of age) mice without TM induction (Figure 2H). No 
changes to the pancreatic histology were observed in the TM-induction group (Supplementary 
Figure 2D). Consistent with a role in tumorigenesis, the p53 mutations occur in 50–75% of 
human PDAC following an initiating mutation in KRAS. To determine if mutant p53 could also 
inhibit pancreatic Fgf21, we employed the fElasCreERT;Trp53LSL-R172H/+ mouse strain.  Five months 
post-TM, no significant differences in pancreatic Fgf21 expression were observed between the 
age-matched Trp53R172H/+ and fElasCreERT mice (Supplementary Figure 2E), indicating that 
KrasG12D/+, but not Trp53R172H/+, specifically induces the marked downregulation of Fgf21. 
Furthermore, we compared Fgfr1 and Klb expression in the age-matched fElasCreERT and 
KrasG12D/+ mice one week post-TM. No significant changes for both genes were noticed 
(Supplementary Figure 2F-G).  
 
Oncogenic KRAS reduces pancreatic Fgf21 expression partially through downregulating 
Pparg 
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To understand how oncogenic KRAS may potentially intervene to suppress FGF21 expression, 
we analyzed the expression of the transcription factors that are known to possess consensus 
binding sites on the Fgf21 promoter region and responsible for Fgf21 expression9, 10, 30-32. 
Among them, peroxisome proliferator-activated receptor gamma (Pparg, which encodes PPAR-
gamma or PPARG), peroxisome proliferator-activated receptor alpha (Ppara), and retinoic acid 
receptor-related orphan receptor (Rora) were significantly downregulated (Figure 2I, 
Supplementary Figure 2H-I) in the same pancreatic tissues where Fgf21 was reduced by 
KrasG12D. However, other known Fgf21-regulating factors, such as Rarb and ChREBP 
(Supplementary Figure 2J-K), as well as SREBP1 and Lxrb (data not shown), were not 
changed. Treatment of mutant KRAS-bearing Panc-1 cells that have a weak FGF21 expression 
with a specific PPARG agonist, Rosiglitazone, resulted in a dose-dependent increase in FGF21 
expression (Figure 2J), suggesting that PPARG is a potential mediator of KRASG12D-
downregulated expression of pancreatic FGF21.  
 
Replenishment of FGF21 inhibits KRASG12D-mediated pancreatic inflammation and PanIN 
lesions under normal dietary conditions 
Studies have demonstrated that under wild-type KRAS conditions, FGF21 signaling was 
induced in acinar cells upon experimental induction of pancreatitis and that genetic deletion of 
Fgf21 exacerbated pancreatic injury19. FGF21 acts directly on acinar cells to promote exocrine 
secretion without increasing protein synthesis, thereby mitigating proteotoxic stress18, 
suggesting that acinar cell FGF21 alleviates metabolic stress and associated pathogenic effects 
in the presence of wild-type KRAS. By contrast, our above data reveal that oncogenic KRAS 
downregulates acinar cell FGF21. 
 
To determine if FGF21 replenishment plays a role in restricting KrasG12D/+-mediated pancreatic 
inflammation and fibrosis under the normal diet (ND) conditions, we administered rhFGF21 to 
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KrasG12D/+ mice for 10 weeks to compensate for the loss of acinar cell FGF21 (Figure 3A). 
rhFGF21 treatment significantly inhibited pancreatic inflammation and immune cell infiltration as 
measured by IHC staining of inducible cyclooxygenase-2 (COX-2) and F4/80, respectively, 
compared to those without rhFGF21 treatment (n=8) (Figure 3B, Supplementary Figure 3A-
B). rhFGF21 also significantly reduced pancreatic fibrosis as measured by Sirius Red staining of 
collagen fibrils (Figure 3B, Supplementary Figure 3C). These data suggest that rhFGF21 
supplementation effectively inhibits pancreatic inflammation and fibrosis induced by KRASG12D 
under the ND conditions. 
 
To test whether rhFGF21 administration could inhibit KRASG12D-mediated acinar-to-ductal 
metaplasia (ADM), we evaluated acinar and duct cell markers in the ND-fed KrasG12D/+ mice 
upon rhFGF21 treatment. Co-immunofluorescence (Co-IF) analyses of amylase and CK19, 
which mark acinar and duct cells, respectively, revealed that rhFGF21 treatment significantly 
reduced CK19+ staining and preserved amylase+ acinar cells compared to those without 
rhFGF21 treatment (Figure 3C-E). These data suggest that rhFGF21 suppresses the ADM 
reprogramming induced by oncogenic KRAS under normal feeding conditions. 
 
To determine whether rhFGF21 directly acts on acinar cells, we isolated acinar cell clusters 
from 80-day-old KrasG12D/+ mice one week post-TM and seeded them in collagen plates for 3-
dimensional (3D) explant cultures with daily rhFGF21 treatment. On day one, treatment with 
rhFGF21 had little effects on the acinar cell clusters; however, by day four, rhFGF21 
significantly inhibited ductal cell formation compared to PBS treatment group (Figure 3F, 
Supplementary Figure 3D), suggesting that rhFGF21 directly acts on acinar cells to inhibit 
KRASG12D-mediated ADM reprogramming.  
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As ADM is regarded as the precursor to the development of PanIN lesions, we evaluated the 
effects of FGF21 administration on KRASG12D-mediated PanIN lesions using Alcian blue staining 
for acidic mucins and IHC staining for Mucin 5AC (MUC5). rhFGF21 injections caused a 
noticeable reduction in both acidic mucins and MUC5 compared to those without FGF21 
treatment (Figure 3G, Supplementary Figure 3E-F). Using IHC analysis, we observed that 
rhFGF21 suppressed ductal cell proliferation as measured by the decreased levels of Ki-67 and 
cyclin D1 (Figure 3H-J). Altogether, our data indicate that the exogenous supplementation of 
FGF21 to KrasG12D/+ mice that have a dramatic reduction of FGF21 in acinar cells results in 
significant beneficial effects on the inhibition of pancreatic inflammation, ADM, and PanIN 
lesions under the ND conditions.  
 
Pharmacological administration of FGF21 inhibits HFD and KRASG12D induced PanIN 
lesions and PDAC  
Inspired by the above data, we proceeded to determine if FGF21 plays a suppressive role in 
HFD and KRAS mediated invasive PDAC by treating the KrasG12D/+ mice concurrently with HFD 
and rhFGF21 for 10 weeks (Figure 4A). The HFD-fed KrasG12D/+ mice accumulated abdominal 
fat and developed multiple pancreatic cysts (Figure 4B). In contrast, treatment with rhFGF21 
alleviated abdominal fat accumulation and pancreatic cysts (Figure 4B). Consistently, rhFGF21 
administration reduced the accumulation of pancreatic triglycerides in comparison to those 
without rhFGF21 treatment (Supplementary Figure 4A). Histological analysis revealed that the 
HFD-fed KrasG12D/+ mice displayed high-grade PanIN lesions and PDAC with 50% penetrance 
(Figure 4C). In marked contrast, with rhFGF21 treatment, most of the mice (87.5%) exhibited 
well-preserved parenchyma and acinar cell content with only early stage PanIN lesions (Figure 
4C-D). Only one out of eight mice treated with rhFGF21 developed PDAC. 
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Assessment of damage to pancreatic tissues revealed that chronic HFD consumption led to a 
significant decrease of amylase, which marks acinar cell content, while rhFGF21 treatment 
restored the lost amylase content (Figure 4E, Supplementary Figure 4B). Alpha-smooth 
muscle actin (α-SMA), which marks the levels of pancreatic stellate cell activation, was strongly 
elevated in the HFD-fed KrasG12D/+ mice. However, this elevation was significantly suppressed 
by chronic treatment with rhFGF21 (Figure 4E, Supplementary Figure 4C). The Co-IF analysis 
further revealed that rhFGF21 greatly reduced CK19+ staining and preserved acinar cells 
(amylase+) compared to the HFD-fed KrasG12D/+ mice without rhFGF21 treatment (Figure 4F, 
Supplementary Figure 4D-E). A similar pattern to that observed for amylase was found for 
MIST1, a transcription factor essential for maintaining an adult acinar cell phenotype (Figure 4F, 
Supplementary Figure 4F). These data suggest that rhFGF21 preserved acinar cells and 
inhibited stromal activation induced by HFD in KrasG12D/+ mice. Furthermore, we observed 
prominent positive stains of acidic mucins and MUC5 in the pancreata of the HFD-fed KrasG12D/+ 
mice; however, rhFGF21 treatment significantly inhibited these PanIN markers (Figure 4G, 
Supplementary Figure 4G-H). Our data suggest that the replenishment of FGF21 suppresses 
HFD and KRASG12D induced rapid PanIN lesions and PDAC. 
 
To determine whether the significant downregulation of pancreatic FGF21 by KRASG12D can 
lead to a reduction of serum FGF21 levels, which may induce systemic metabolic alterations, 
we measured serum FGF21 levels pre-TM, one week and 10 weeks post-TM induction of 
KrasG12D/+. No significant differences in serum FGF21 levels were observed (Supplementary 
Figure 4I-J), indicating that alteration of pancreatic FGF21 by KRASG12D does not influence 
circulating FGF21 levels. 
 
Pharmacological FGF21 inhibits HFD and KRASG12D induced pancreatic inflammation  
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Chronic HFD causes inflammation, which cooperates with oncogenic KRAS to drive PDAC4. To 
understand whether the tumor-suppressive effect of rhFGF21 is through alleviation of pancreatic 
inflammation, we analyzed the protein expression of COX-2, which was up-regulated in the 
HFD-fed KrasG12D/+ mice6. Indeed, these mice exhibited intense focal staining of COX-2 along 
the pancreatic ducts; however, rhFGF21 treatment significantly decreased COX-2+ staining to 
levels comparable to the ND-fed KrasG12D/+ mice (Figure 5A, Supplementary Figure 5A).  
Furthermore, macrophages, as detected by F4/80+ staining, were abundant in the pancreata of 
the HFD-fed KrasG12D/+ mice; however, rhFGF21 significantly inhibited HFD-induced 
macrophage infiltration (Figure 5A, Supplementary Figure 5B). In a similar manner, CD3, as a 
marker of peripheral T cell infiltration, was significantly elevated under chronic HFD insult, while 
rhFGF21 alleviated T cell infiltration (Figure 5A, Supplementary Figure 5C). Analysis of 
extracellular matrix collagen deposition that marks pancreatic fibrosis revealed that although the 
ND-fed fElasCreERT mice displayed a minimal collagen staining that was primarily localized 
around the blood vessels and the peri-lobular spaces, the HFD-fed KrasG12D/+ mice exhibited 
intense collagen deposition surrounding the neoplastic ductal structures, indicating a robust 
fibrotic response. In contrast, FGF21 supplementation significantly reduced collagen levels 
(Figures 5A, Supplementary Figure 5D).  
 
To better understand the suppressive role of FGF21 in pancreatic inflammation promoted by the 
cooperative interaction between HFD and KRASG12D, we analyzed the expression of an array of 
inflammation-associated cytokines/chemokines and receptors comparatively by qRT-PCR. Of 
note, the pancreata of the ND-fed KrasG12D/+ mice showed significant increases in the expression 
of Cxcl5, Tgfb1, Ccl2, Csf2, Tnf, and Tnfrsf11b in comparison to those of the ND-fed fElasCreERT 
mice, suggesting that pancreatic inflammation is mediated by oncogenic KRAS in this context 
(Figure 5B-C, Supplementary Figure 5E-H). HFD treatment further enhanced the expression 
of these genes (Figure 5B-C, Supplementary Figure 5E-H), indicating a significant 
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inflammatory effect of obesogenic HFD on the pancreas. Interestingly, although pancreatic 
Ccl17 was not affected by KRASG12D under the ND conditions, it was markedly upregulated in 
response to the HFD challenge in the KrasG12D/+ mice (Supplementary Figure 5I). Importantly, 
rhFGF21 administration significantly suppressed the augmented expression of all these genes 
(Figure 5B-C, Supplementary Figure 5E-I). These data suggest a prominent anti-inflammatory 
role of FGF21 in the pancreas. On the other hand, the expression levels of the cytokines that 
have anti-inflammation or anti-neoplastic functions, including Ccl19, Ifng, Il21, Cd40l, Ccl21a, 
and Cxcl9, were significantly downregulated in the HFD-fed KrasG12D/+ mice, while administration 
of rhFGF21 effectively restored their expression (Supplementary Figure 5J-O).  
 
We have previously shown that RAS activity is an important determinant in pancreatic 
tumorigenesis, and that inflammation enhances RAS activity21, 33. As pharmacological rhFGF21 
significantly suppressed HFD-promoted pancreatic inflammation, we tested if this would lead to 
a reduction of RAS activity in the pancreata of the HFD-fed KrasG12D/+ mice. Indeed, we 
observed that the HFD-enhanced RAS hyperactivity was significantly inhibited by rhFGF21 
(Figure 5D, Supplementary Figure 5P). These data indicate that the beneficial effects of 
FGF21 in protecting the pancreas from neoplastic progression are attributable to the inhibition of 
the accentuated inflammation and RAS hyperactivation induced by HFD.  
  
Correspondingly, rhFGF21 treatment significantly reduced cyclin D1 and Ki-67 levels in the 
pancreatic ductal cells of the HFD-fed KrasG12D/+ mice compared to those without rhFGF21 
treatment (Figure 5E, Supplementary Figure 5Q-R). These data indicate that the 
supplementation of rhFGF21 to compensate for the loss of pancreatic FGF21 inhibits pancreatic 
tumor cell proliferation induced by the synergistic cooperation between KRASG12D and HFD.  
 
Pharmacological FGF21 inhibits HFD-induced liver and adipose tissue inflammation 
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As chronic HFD imposes adverse metabolic effects on adipose tissue and the liver, which are 
among the direct or indirect targets of endocrine FGF219, 10, 16, we therefore tested the anti-
inflammatory effects of rhFGF21 on both tissues. The ND-fed KrasG12D/+ mice showed no 
significant differences in the inflammation markers compared to the ND-fed fElasCreERT mice in 
either the liver or the adipose tissue (Figure 6A-I, Supplementary Figure 6A-B), suggesting 
that the liver and adipose tissue do not impose significant inflammatory stress on the pancreas 
under the ND conditions, and therefore, the observed pancreatic inflammation and associated 
pathologies in Figure 3 are attributable to KRASG12D in this context. Thus, FGF21 plays a direct 
role in restricting KRASG12D-mediated pancreatic inflammation and associated pathogenesis.  
 
Furthermore, chronic HFD significantly elevated the expression of Ccl2, Ccl4, CD68, and 
CD11b in both the liver and adipose tissues, as well as adipose Tgfb1, Tnf, and Ccl11, while 
rhFGF21 effectively suppressed these inflammation markers (Figure 6A-I, Supplementary 
Figure 6A-B). As a metabolic marker of adipose tissue response, adipose Ucp1 underwent a 
striking increase of >40 fold with rhFGF21 treatment (Supplementary Figure 6C). Furthermore, 
the anti-inflammatory and anti-fibrotic adipokine, Adipoq, was also significantly elevated upon 
rhFGF21 treatment (Supplementary Figure 6D). These data suggest that rhFGF21 inhibits the 
HFD-induced systemic inflammation that otherwise may impinge on the pancreas through 
secretory cytokines or adipokines. 
 
Pharmacological FGF21 inhibits HFD and KRASG12D induced liver metastasis and 
prolongs survival  
Next, we determined whether pharmacological administration of rhFGF21 would prolong the 
overall survival and inhibit liver metastasis in the HFD-fed KrasG12D/+ mice. We first observed 
that mice fed a HFD had a substantial increase in body weight; however, this was not evident 
under rhFGF21 treatment despite a continued HFD consumption (Figure 7A). Furthermore, the 
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survival rate of the HFD-fed KrasG12D/+ mice significantly decreased compared to the age-
matched ND-fed KrasG12D/+ mice, with median survival rates of 229 days and 352 days, 
respectively. Treatment with rhFGF21 prolonged the median survival of the HFD-fed KrasG12D/+ 
to 323 days (Figure 7B). KrasG12D/+ mice fed a ND and concurrently treated with rhFGF21 
showed a better survival rate than the ND-fed KrasG12D/+ mice (Figure 7B), which do not 
spontaneously develop obesity. Regardless of the nature of the diets and the survival rates, the 
aged KrasG12D/+ mice eventually developed PDAC (Figure 7C). The cancerous cells formed 
ductal structures (closed arrow), showing severe architectural and cytological atypia with 
frequent mitotic figures and abundant interstitial fibrosis (Figure 7C). 
 
Over 50% of the HFD-fed KrasG12D/+ mice progressed to liver metastasis. Multiple metastatic 
nodules with distinct borders were mostly found located on the liver surface in the HFD 
treatment group (Figure 7D, upper panel). Histological analyses revealed prominent metastatic 
foci on liver sections of the HFD treatment mice (Figure 7D, middle panel), and CK19 positive 
staining further confirmed the liver metastases in the HFD-fed KrasG12D/+ mice. In contrast, the 
HFD-fed KrasG12D/+ mice concurrently treated with rhFGF21 failed to develop liver metastases 
(Figure 7D, lower panel, Supplementary Figure 7A).  
 
In summary, our studies show that KRASG12D, partly through downregulating Pparg, reduces 
Fgf21, which in turn creates a vulnerability to obesogenic HFD challenge, leading to extensive 
inflammation, RAS hyperactivation, PanIN lesions, and invasive PDAC. Pharmacological 
supplementation of FGF21 mitigates both pancreatic and systemic inflammation, resulting in the 
suppression of RAS hyperactivity and PDAC development (Figure 7E).    
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Discussion 
 
Obesity dramatically increases the risk of pancreatic cancer, which remains one of the most 
aggressive malignancies34, and the chronic consumption of a HFD is known as a primary dietary 
factor in promoting obesity. As the prevalence of obesity has been increasing at an alarming 
rate, obesity-associated pancreatic cancer poses an even greater threat. Thus, gaining a better 
understanding of HFD-promoted pancreatic cancer is urgent, as it will provide new insights into 
possible effective intervention strategies. Experimentally, HFD promotes oncogenic KRAS-
mediated PDAC, indicating that mutations in KRAS render mice susceptible to obesogenic HFD 
insults leading to PDAC. However, the mechanism underlying such vulnerability is unclear. In 
this study, we made several novel observations concerning the roles of FGF21, metabolic 
regulator that prevents obesity, in the pancreas and oncogenic KRAS-mediated pancreatic 
tumorigenesis. First, we find that acinar cells express high levels of Fgf21, Fgfr1, and Klb under 
normal feeding conditions, suggesting that acinar cells are both a source and a target of FGF21. 
Second, we report for the first time that Fgf21 expression in acinar cells is highly sensitive to 
mutant KRASG12D, showing remarkable decrease upon the expression of KrasG12D/+ at an 
endogenous level when no overt alterations of pancreatic histology are noted. Third, we show 
that the significant downregulation of Fgf21 by mutant KRASG12D is partly mediated by the 
reduced PPARG. Fourth, we note that replenishment of the lost FGF21 directly inhibits 
pancreatic inflammation, transdifferentiation of acinar cells into ductal cells, and PanIN lesions 
under the ND conditions. Fifth, pharmacological FGF21 significantly mitigates inflammation in 
both the pancreas and systemic liver and adipose tissue under the HFD conditions. Sixth, 
FGF21 supplementation significantly inhibits HFD-promoted pancreatic RAS hyperactivity. 
Finally, pharmacological FGF21 significantly ameliorates pancreatic pathogenic responses, 
leading to the significant delay of PDAC development and extension of survival under 
obesogenic HFD challenge.   
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We have provided evidence to support that KRASG12D downregulates pancreatic FGF21 
expression. First, we show that PADC patient tissues and mutant KRAS-bearing pancreatic 
cancer cells exhibit a significant reduction of FGF21 compared to their normal counterparts. 
Second, in several KrasG12D/+ mouse strains with different Cre drivers, we show that KRASG12D 
significantly inhibits Fgf21 expression. Third, we note that Pparg, Ppara, and Rora, which were 
shown to induce FGF21 expression9, 10, 30-32, are downregulated by KRASG12D expression. Finally, 
treatment of pancreatic cancer cells with PPARG agonist increased FGF21 expression in a 
dose-dependent manner, suggesting a role of PPARG in regulating pancreatic FGF21. It would 
be interesting to investigate further the functional roles of PPARG, PPARA, and RORA in 
regulating pancreatic FGF21 and pancreatic tumorigenesis.  
 
Our results indicate a prominent role of FGF21 in directly protecting the pancreas from 
neoplastic progression induced by KRASG12D. First, we show that acinar cells express high 
levels of FGF21 and its receptor complex, indicating an autocrine/paracrine mode of FGF21 
action in the pancreas, which aligns with previous findings showing that FGF21 directly targets 
acinar cells18, 19. Second, the pancreata of the ND-fed KrasG12D/+ mice, which do not develop 
obesity and systemic inflammation, were effectively protected from KRASG12D-driven 
inflammation and neoplastic progression by rhFGF21, indicating a direct protective effect of 
FGF21 on the pancreas with minimal systemic influence. Third, we show that rhFGF21 directly 
inhibits ADM in the in vitro 3D explant cultures of acinar clusters, which is not subject to 
systemic metabolic influence.  
 
Pancreatic function and systemic metabolism are inextricably linked. In the KrasG12D/+ mice, 
chronic consumption of HFD leads to obesity and invasive PDAC, while rhFGF21 ameliorates 
these detrimental systemic and local pancreatic effects of HFD. We show that HFD induces 
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inflammation in both the pancreas and systemic liver and adipose tissue, while these adverse 
effects are effectively inhibited by rhFGF21, emphasizing the broad anti-inflammatory role of 
FGF21. Decreased inflammation was accompanied by the suppression of inflammation-
associated fibrosis, PanIN lesions, and PDAC development. Importantly, we observed that the 
HFD-enhanced pancreatic RAS activity was also significantly reduced by rhFGF21. Furthermore, 
previous studies have shown that inhibition of local pancreatic inflammation through ablation of 
COX-2 in acinar cells markedly suppressed HFD and KRASG12D mediated pancreatic neoplastic 
progression6, supporting that the inhibition of local pancreatic inflammation is critical to the 
suppression of pancreatic tumorigenesis. Collectively, our data suggest that in addition to the 
noticeable systemic anti-inflammatory effects, the anti-inflammatory effects of rhFGF21 on the 
pancreas are essential to the suppression of HFD-promoted inflammatory damage and RAS 
hyperactivation, leading to the protection of the pancreas from neoplastic progression. 
 
Previous studies focused on the pathophysiological roles of FGF21 in the liver and pancreas in 
the setting of wild-type KRAS18, 19, 35, which showed that FGF21 exhibits a marked elevation in 
response to stress-inducing conditions, including the ingestion of a HFD11. Unlike these 
previous studies, however, our study shows that pancreatic FGF21 is negatively regulated by 
oncogenic KRAS. By abrogating FGF21, oncogenic KRAS allows the malevolent metabolic 
effect of chronic HFD consumption to take its maximal toll on the pancreas. In light of this fact, 
the loss of pancreatic FGF21 specifically by oncogenic KRAS is significant, as this breaks a 
stress-defensive barrier in the path towards PDAC development.  
 
We observed multiple small pancreatic cysts in the HFD-fed KrasG12D/+ mice; however, rhFGF21 
treatment effectively inhibited this phenomenon, suggesting that inflammation is likely the cause 
of pancreatic cysts. In patients, mucinous cystic lesions are precursors to invasive pancreatic 
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cancer. Therefore, it is possible that FGF21 holds the potential to reverse mucinous pancreatic 
cysts and reduce the risk of pancreatic cancer in such patients.  
 
In summary, our findings reveal a previously unknown critical vulnerability conferred by 
oncogenic KRAS, highlight pancreatic FGF21 as an important downstream target of oncogenic 
KRAS, and identify pharmacological FGF21 as a putative intervention strategy to hinder 
pancreatic inflammation and cancer development in the context of obesity.  
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FIGURE LEGENDS 
Figure 1. Pancreatic acinar cells are both a source and a target of FGF21.  
All mice in A-H were fed a ND, induced by TM at 70 days of age, and sacrificed one week post-
TM. (A) qRT-PCR analysis of Fgf21 expression in the liver (n=11) and pancreas (Panc, n=11) of 
fElasCreERT mice. (B) IHC analysis of FGF21 on the liver and pancreas sections. 200x. (C) 
Western blot analysis for FGF21 levels. (D) Semi-quantitative RT-PCR analysis for Fgfr1 in the 
liver (L) and pancreas (P). (E-F) qRT-PCR analysis for Fgfr1 and Klb in the liver (n=9) and 
pancreas (n=9). (G) Western blot analysis for KLB in the pancreas (p). (H) IHC analysis of KLB 
in pancreatic sections. 200x. All mice in I-K were fed a ND, induced by TM at 70 days of age, 
and sacrificed at 7 months of age. Comparative qRT-PCR analysis for Fgf21 (I), Fgfr1 (J) and 
Klb (K) in the liver (n=7), pancreas (n=7), and adipose tissue (n=7) of fElasCreERT mice. Open 
arrow, acinar cells. Closed arrow, islet cells. Data are means ± SEM. *, p<0.05; **, p<0.01; ****, 
p<0.0001; ns, not significant. 
 
 
Figure 2. KRASG12D downregulates Fgf21 gene expression in acinar cells.  
(A) IHC analysis for FGF21 levels in tissue arrays of human normal pancreas (n=45) and PDAC 
(n=59) (40x). Inset: 200x. (B) Quantitation of human FGF21 levels as described in 2A. (C) 
Human FGF21 expression in 39 pairs of normal and tumor tissues resected from pancreatic 
cancer patients as collected in the GEO database 
(https://www.ncbi.nlm.nih.gov/geo/tools/profileGraph.cgi?ID=GDS4103:221433_at). (D) qRT-
PCR analysis of FGF21 in human pancreatic cancer cell lines carrying KRAS mutations. Human 
normal pancreatic ductal epithelial (HPDE) cells served as a control. All mice in E-I were fed a 
ND. (E) qRT-PCR analysis of pancreatic Fgf21 in 7-month-old KrasG12D/+ (n=11) or fElasCreERT 
mice (n=5) mice five months post-TM. (F) qRT-PCR analysis of pancreatic Fgf21 in 40-day-old 
KrasG12D/+ mice one week post-TM (n=7) or without TM (n=9). (G) Representative histology of 
the pancreata as in 2F. 200x. (H) qRT-PCR analysis of pancreatic Fgf21 of two-month-old 
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Ptf1aCreERT;KrasG12D/+ mice two weeks post-TM (n=3) or without TM (n=3). (I) qRT-PCR analysis 
of pancreatic Pparg in 40-day-old KrasG12D/+ mice one week post-TM (n=7) or without TM (n=9). 
(J) qRT-PCR analysis of FGF21 in Panc-1 cells with Rosiglitazone treatment. Data are mean ± 
SD. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
 
Figure 3. Replenishment of FGF21 suppresses KRASG12D-induced pancreatic 
inflammation and PanIN lesions under ND conditions. 
(A) Experimental scheme for B-E and G-J: 70-day-old ND-fed KrasG12D/+;fElasCreERT mice were 
treated with TM at 70 days of age to induce KrasG12D/+ expression in acinar cells, and then 
treated with rhFGF21 (0.5 mg/kg body weight/day) (n=10) or PBS (n=8) for ten weeks. (B) IHC 
staining of COX-2 and F4/80, and Sirius Red staining of collagen on pancreatic sections of 
KrasG12D/+ mice with indicated treatments. 200x. (C) Co-immunofluorescence (Co-IF) analysis of 
amylase and CK19 as indicated. 200x. (D-E) Quantitation of amylase+ areas or CK19+ areas 
on pancreatic sections (n=4) as described in 3C. (F) The explanted acinar cell 3D clusters 
isolated from 80-day-old KrasG12D/+ mice one week post-TM were treated daily with rhFGF21 or 
PBS and then analyzed by brightfield images on day 1, H&E staining on day 4, and Co-IF 
staining of amylase and CK19 on day 4. (G) Alcian blue staining of acidic mucins and IHC 
staining of MUC5. (H) IHC analyses of Ki-67 (ND, n=4; ND+rhFGF21, n=4) and Cyclin D1 (ND, 
n=5; ND+rhFGF21, n=3). (I-J) Quantitation of Ki-67 and Cyclin D1 levels in 3H. Results were 
expressed as mean ± SD. **, p<0.01. 
 
 
Figure 4. Supplementation of FGF21 suppresses HFD and KRASG12D induced PanIN 
lesions and PDAC. 
(A) Experimental scheme: 70-day-old ND-fed KrasG12D/+;fElasCreERT mice were treated with TM to 
induce KrasG12D/+ expression and randomly separated into ND, HFD, or HFD with rhFGF21 
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treatment groups (n=8 per group) for ten weeks. The age-matched ND-fed fElasCreERT mice (n=8) 
served as controls. (B) Gross images of KrasG12D/+ mice (left) and the pancreata (right) after the 
indicated treatments. Closed arrows, multiple pancreatic cysts. (C) Histology of representative 
pancreata. Closed arrows, PanIN lesions. Open arrows, cancerous ductal structure. 100x. (D) 
Average grades of PanIN1/2 and PanIN3 lesions as in 4C. F21, rhFGF21. (E) Western blot 
analysis of pancreatic amylase and α-SMA as indicated. (F) Co-IF analysis of pancreatic 
amylase and CK19 or IHC analysis of MIST1. 200x. (G) Alcian blue+ staining of acidic mucins 
and IHC staining of MUC5. 200x. Data are mean ± SD. *, p<0.05; **, p<0.01. 
 
Figure 5. Pharmacological FGF21 inhibits HFD and KRASG12D induced pancreatic 
inflammation and ductal cell proliferation. 
All the samples were described as in Figure 4A. (A) IHC staining of COX-2, F4/80, and CD3, as 
well as Sirius Red staining for collagen on pancreatic sections of KrasG12D/+ mice. 200x. (B-C) 
qRT-PCR analysis of pancreatic Cxcl5 and Tgfb1 expression in KrasG12D/+ mice with ND (n=4), 
HFD (n=4) or HFD+rhFGF21 (n=5). The age-matched ND-fed fElasCreERT mice (n=5) served as a 
control. (D) Pancreatic RAS activity with the indicated treatments. (E) IHC staining of pancreatic 
cyclin D1 and Ki-67. 200x. Data are mean ± SD. *, p<0.05; **, p<0.01; ****, p<0.0001.  
 
Figure 6. Pharmacological FGF21 inhibits HFD-promoted liver and adipose tissue 
inflammation  
All mice were induced by TM at 70 days of age and then treated as indicated for 10 weeks prior 
to analyses. qRT-PCR analysis of Ccl2, Ccl4, CD68, CD11b, and Tgfb1 in adipose tissues (A-E) 
and Ccl2, Ccl4, CD68, and CD11b in the liver (F-I) of KrasG12D/+ mice with ND (n=5), HFD (n=6), 
or HFD+rhFGF21 (n=5). The ND-fed fElasCreERT mice (n=5) were controls. Data are mean ± SD. 
*, p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 7. Pharmacological FGF21 prevents liver metastasis and prolongs KRASG12D mice 
survival. 
70-day-old mice were treated with TM to induce fElasCreERT or KrasG12D/+ expression, and then 
fed a ND or a HFD with or without rhFGF21 until they aged. The ND-fed fElasCreERT mice (n=7) 
were controls. (A) Body weight of the KrasG12D/+ mice with ND (n=7), HFD (n=7), or 
HFD+rhFGF21 treatment (n=7) until the HFD group aged. (B) Survival of the KrasG12D/+ mice 
with ND (n=7), ND+rhFGF21 (n=10), HFD (n=7), or HFD+rhFGF21 treatment (n=7). The HFD-
fed KrasG12D/+ mice served as a control for statistical comparison. (C) Histological changes in 
pancreata of KrasG12D/+ mice with the indicated treatments upon aging. 200x. (D) Liver 
metastasis. Upper panel, gross images of the livers. Middle panel, H&E stained sections. Lower 
panel, IHC analysis of CK19. (E) Schematic summary of the role of pancreatic FGF21 in the 
HFD and oncogenic KRAS mediated pancreatic tumorigenesis. 200x. Data are mean ± SD. *, 
p<0.05; ***, p<0.001; ****, p<0.0001. 
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WHAT YOU NEED TO KNOW 
 
BACKGROUND AND CONTEXT: A high-fat diet (HFD) promotes obesity, which increases the 
risk of pancreatic cancer. In mice, a HFD and expression of oncogenic KRAS lead to the 
development of pancreatic cancer. We investigated how the expression of oncogenic KRAS 
regulates fibroblast growth factor 21 (FGF21), which prevents obesity, and the effects of FGF21 
administration on pancreatic tumorigenesis. 
 
NEW FINDINGS: Normal acinar cells from mice and humans express high levels of FGF21. In 
mice, acinar expression of oncogenic KRAS significantly reduces FGF21 expression. When 
these mice are placed on a HFD, they develop extensive inflammation, pancreatic cysts, 
pancreatic intraepithelial neoplasias, and pancreatic adenocarcinomas—all were reduced by 
injection of FGF21. FGF21 reduces HFD-promoted RAS activity. 
 
LIMITATIONS: These studies were performed in mice—more studies of humans are needed. 
 
IMPACT: FGF21 is downregulated by oncogenic KRAS. FGF21 might be given to patients for 
the prevention or treatment of pancreatic cancer. 
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Lay Summary 
 
 A high-fat diet promotes development of pancreatic cancer. We found that acinar cells that 
express oncogenic KRAS reduce expression of fibroblast growth factor 21. In mice on a high-fat 
diet, injection of fibroblast growth factor 21 reduces pancreatic inflammation and tumor 
development. 
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1. Supplementary Figures 
 
Supplementary Figure 1 
 
 
 
Supplementary Figure 1, relating to Figure 1. (A) qRT-PCR analysis of the 
expression levels of Fgf21 in pancreatic tissues from 80-day-old fElasCreERT mice (n=4) 
one week post-TM induction, and from 7-month-old fElasCreERT mice (n=6) five months 
post-TM induction. All the mice were fed a normal diet for the duration of the 
experiments. Results indicate that pancreatic Fgf21 gene expression remains 
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unchanged with age in the fElasCreERT mice. Results are expressed as mean ± SD. p 
values are determined by the Student’s t-test. ns, not significant.  
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Supplementary Figure 2 
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Supplementary Figure 2, relating to Figure 2. (A) Representative IHC staining of 
FGF21 in tissue arrays of normal human pancreata (left) and PDAC specimens (right) 
(40x). Inset: normal ducts, 200x. (B) Representative IHC analysis of FGF21 levels in 7-
month-old KrasG12D/+ mice 5 months post-TM induction. 200x. (C) qRT-PCR analysis for 
Fgf21 expression in 40-day-old fElasCreERT mice one week after TM induction (n=11) or 
without TM induction (n=6). (D) Representative H&E staining of the pancreatic tissue 
sections in the Ptf1αCreERT;KrasG12D/+ mice with or without TM induction as in Figure 2H. 
(E) qRT-PCR analysis of Fgf21 expression in pancreatic tissues obtained from 7-month-
old fElasCreERT (n=3) and Trp53R172H/+ (n=4) mice five months post-TM induction. (F) 
qRT-PCR analysis of pancreatic Fgfr1 expression in 80-day-old KrasG12D/+ mice (n=5) or 
fElasCreERT mice (n=4), one week post-TM treatment. (G) qRT-PCR analysis for 
pancreatic Klb expression in 80-day-old adult KrasG12D/+ mice (n=9) or fElasCreERT mice 
(n=6), one week after TM treatment. (H-K) qRT-PCR analysis for pancreatic Ppara, 
Rora, Rarb, and ChREBP expression in 40-day-old KrasG12D/+ mice (n=6) or fElasCreERT 
mice (n=6) one week post-TM induction. All the mice were fed a ND. Results are 
expressed as mean ± SD. p values are determined by the Student’s t-test. ns: no 
significance. **, p<0.01. 
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Supplementary Figure 3 
 
Supplementary Figure 3, relating to Figure 3. (A-B) Quantitative analysis of COX-2+ 
or F4/80+ areas in the KrasG12D/+ mice with ND (n=4) or ND+rhFGF21 (n=4) treatment 
using images as represented in Figure 3B. (C) Quantitative analysis of Collagen+ areas 
in the KrasG12D/+ mice with ND (n=6) or ND+rhFGF21 (n=5) treatment using images as 
represented in Figure 3B. (D) Quantification of the percentage of tubular ductal 
structures in the entire acinar clusters on day 4 after the indicated treatments with three 
independent experiments as shown in Figure 3F. (E) Quantitative analysis of Alcian 
blue+ areas over total areas in the KrasG12D/+ mice with ND (n=6) or ND+rhFGF21 (n=6) 
treatment using images as represented in Figure 3G. (F) Quantitative analysis of 
MUC5+ areas in the KrasG12D/+ mice with ND (n=5) or ND+rhFGF21 (n=5) treatment 
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using images as represented in Figure 3G. Fiji ImageJ software was used to obtain 
image data for statistical analyses. Results are expressed as mean ± SD. p values are 
determined by the Student’s t-test. *, p<0.05; **, p<0.01; ***, p<0.001.  
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Supplementary Figure 4 
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Supplementary Figure 4, relating to Figure 4. (A) Triglyceride levels in the pancreata 
were quantitatively analyzed in KrasG12D/+ mice with the indicated treatments for 10 
weeks. (B-C) Quantitative analysis of amylase or α-SMA protein levels from three 
independent Western blot data as represented in Figure 4E. (D-E) Quantitative 
analyses of amylase+ or CK19+ areas from the Co-IF imaging data from four different 
mice in each group as represented in Figure 4F. (F) Quantitative analysis of MIST1+ 
areas from IHC data of five different mice in each group as represented in Figure 4F. 
(G-H) Quantitative analysis of Alcian blue+ or MUC5+ areas over total areas using 
images after HFD (n=3) or HFD+rhFGF21 (n=3) treatment as represented in Figure 4G. 
(I) Serum FGF21 levels from the fElasCreERT mice before (n=11) and one week post-TM 
treatment (n=11) and from the KrasG12D/+ mice before (n=29) and one week post-TM 
treatment (n=31). Mice at 70 days of age were treated with TM and serum FGF21 levels 
were measured using Quantikine FGF21 ELISA kits. (J) 70-day-old KrasG12D/+ and 
fElasCreERT mice were treated with TM for 5 consecutive days followed by 10 weeks of 
the indicated treatments. Serum FGF21 levels were then compared using Quantikine 
FGF21 ELISA kits in the KrasG12D/+ mice and the fElasCreERT mice. Data from 4I and 4J 
suggest that pancreatic Fgf21 gene silencing by KrasG12D did not impact systemic 
FGF21 levels. No significant differences in serum FGF21 levels were observed in the 
HFD-fed KrasG12D/+ mice regardless of rhFGF21 treatment, even though an increased 
tendency of serum FGF21 levels were observed in the group with concurrent HFD and 
rhFGF21 treatment, suggesting that rhFGF21 treatment did not significantly alter serum 
FGF21 levels. However, KrasG12D/+ mice treated with either a HFD or HFD+rhFGF21 
had significantly higher levels of serum FGF21 compared to that of the ND-fed 
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KrasG12D/+ mice, suggesting that the increased serum FGF21 was induced mainly by 
HFD. Fiji ImageJ software was used to obtain data from IHC images for statistical 
analysis. Results are expressed as mean ± SD. p values are determined by the 
Student’s t-test. ns, not significant, *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.  
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Supplementary Figure 5 
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Supplementary Figure 5, relating to Figure 5. All tissue samples in the following 
analyses were described as in Figure 4A. The ND-fed fElasCreERT mice (n=4) served as 
normal control. (A-D) Quantitative analysis of COX-2+, F4/80+, CD3+, and collagen-
positive areas in KrasG12D/+ mice with ND (n=4), HFD (n=4) or HFD+rhFGF21 (n=5) 
treatment as represented in Figure 5A. (E-O) qRT-PCR analysis of pancreatic Ccl2, 
Csf2, Tnf, Tnfrsf11b, Ccl17, Ccl19, Ifng, Il21, Cd40l, Ccl21a, and Cxcl9 in the KrasG12D/+ 
mice with ND (n=4), HFD (n=4) or HFD+rhFGF21 (n=5) treatment. (P) Quantitative 
analysis of pancreatic RAS activity from three independent RAS activity experiments as 
represented in Figure 5D. (Q) Quantitative analysis of Cyclin D1+ areas in the 
pancreata of KrasG12D/+ mice with ND (n=4), HFD (n=4) or HFD+rhFGF21 (n=4) 
treatment as represented in the upper panel of Figure 5E. (R) Quantitative analysis of 
Ki-67+ areas in the pancreata of KrasG12D/+ mice with ND (n=4), HFD (n=6) or 
K
i-
6
7
 
c
e
ll
 
p
ro
li
fe
ra
ti
o
n
 
in
d
e
x
 
(%
)
0
1 0
2 0
3 0
4 0
     N D           N D          H F D     H F D + r h F G F 2 1
fE la C r e E R T K r a s G 1 2 D /+
* ** * *
* * * *
* * * *
C
y
c
li
n
D
1
+
 
a
re
a
/t
o
ta
l 
a
r
e
a
,
 
%
0
5
1 0
1 5
** **
N D           N D           H F D      H F D + r h F G F 2 1
fE la s C r e E R T              K r a s G 1 2 D /+
***
* * * *
0
5
1 0
1 5
R
e
la
ti
v
e
 
R
A
S
 
a
c
ti
v
it
y * *
E las C r e E R T             K r a s G 1 2 D /+
N D             N D            H F D      H F D + r h F G F 2 1
* *
* *
P Q R 
N D N D H F D H F D + r h F G F 2 1
0
2
4
6
R
e
la
ti
v
e
C
c
l2
1a
 
m
R
N
A
 
le
v
e
l
fE la s C r e E R T K ra s G 1 2 D /+
*
* *
* *
*
* *
N D N D H F D H F D + r h F G F 2 1
0
1
2
3
R
e
la
ti
v
e
C
d
4
0
l 
m
R
N
A
 
le
v
e
l
fE la s C r e E R T K r a s G 1 2 D /+
*
* *
*
N D N D H F D H F D + r h F G F 2 1
0
1
2
R
e
la
ti
v
e
C
x
c
l9
 
m
R
N
A
 
le
v
e
l
fE la s C re E R T K r a s G 1 2 D /+
*
* *
*
*
M N O 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
  
 14 
HFD+rhFGF21 (n=6) treatment as represented in the lower panel of Figure 5E. Fiji 
ImageJ software was used to obtain data from IHC images for statistical analysis. 
Results are expressed as mean ± SD. p values are determined by the Student’s t-test. 
*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.  
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Supplementary Figure 6 
 
 
 
Supplementary Figure 6, relating to Figure 6. All mice were induced by TM at 70 
days of age and then received the indicated treatments for 10 weeks prior to qRT-PCR 
analysis. (A-D) qRT-P R analyses of adipose Tnf, Ccl11, Ucp1, and Adipoq gene 
expression in KrasG12D/+ mice with ND (n=5), HFD (n=6) or HFD+rhFGF21 (n=5). The 
ND-fed fElasCreERT mice (n=5) served as a control. Results are expressed as mean ± 
SD. p values are determined by the Student’s t-test. *, p<0.05; **, p<0.01; ***, p<0.001; 
****, p<0.0001.  
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Supplementary Figure 7 
 
Supplementary Figure 7, relating to Figure 7. (A) Quantitative analysis of CK19+ 
areas in the representative liver images of KrasG12D/+ mice with ND (n=4), HFD (n=6) or 
HFD+rhFGF21 (n=6) treatment as represented in Figure 7D (lower panel).   Results are 
expressed as mean ± SD. p values are determined by the Student’s t-test. ****, 
p<0.0001. 
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2. Supplementary Table 1 
  
Supplementary Table 1. List of primer sets for qRT-PCR assessment of expression of 
different genes. 
Gene symbol Forward primer Reverse primer 
Fgf21 5’-TTCAAATCCTGGGTGTCAAA-3’ 5’-CAGCAGCAGTTCTCTGAAGC-3’ 
hFGF21 5’-CGGGAGCTGCTTCTTGAGGA-3’ 5’-CTGGTAGTGGCAGGAAGCGA-3’ 
Fgfr1 5’-CTGAAGGAGGGTCATCGAAT-3’ 5’-GTCCAGGTCTTCCACCAACT-3’ 
Klb 5’-CAGAGAAGGAGGAGGTGAGG-3’ 5’-CAGCACCTGCCTTAAGTTGA-3’ 
β-actin  5’-CGGTTCCGATGCCCTGAGGCTCTT-3’ 5’-CGTCACACTTCATGATGGAATTGA-3’ 
18S rRNA 5’-GCAATTATTCCCCATGAACG-3’ 5’-GGCCTCACTAAACCATCCAA-3’ 
Cxcl5 5’-GGAGCTGCGTTGTGTTTGCT-3’ 5’-ACTTCCACCGTAGGGCACTG-3’ 
Tgfβ1 5’-CCCGTGGCTTCTAGTGCTGA-3’ 5’-ACAGGATCTGGCCACGGATG-3’ 
Ccl2 5’-GCATCTGCCCTAAGGTCTTC-3’ 5’-AAGTGCTTGAGGTGGTTGTG-3’ 
Csf2 5’-TTTACTTTTCCTGGGCATTG-3’ 5’-TAGCTGGCTGTCATGTTCAA-3’ 
Tnf 5’-ATGAGAAGTTCCCAAATGGC-3’ 5’-CTCCACTTGGTGGTTTGCTA-3’ 
Ccl17 5’-CCGAGAGTGCTGCCTGGATT-3’ 5’-GAGCTTGCCCTGGACAGTCA-3’ 
Ccl19 5’-TCAGCTCTGTGCACCTCCAG-3’ 5’-GCTCCTTCTGGTGCTGTTGC-3’ 
Tnfrsf11b 5’-CATCTCGGCCACTCGAACCT-3’ 5’-AGGAGCTGCTCGCTCGATTT-3’ 
Ccl4 5’-AGCAACACCATGAAGCTCTG-3’ 5’-CCGGGAGGTGTAAGAGAAAC-3’ 
CD68 5’-CCGGACCCACAACTGTCACT-3’ 5’-GAGGGCCAACAGTGGAGGAT-3’ 
CD11b 5’-GCCTCCCTTTGCTCTGTGGA-3’ 5’-CTCGAGGCAAGGGACACACT-3’ 
Ucp1 5’-CTCGAGGCAAGGGACACACT-3’ 5’-AAAGGACTCAGCCCTGAAGA-3’ 
Ifng 5’- CATTCAGAGCTGCAGTGACC-3’ 5’- CTGTCTGGCCTGCTGTTAAA-3’ 
Il21 5’-GGCCATTCCCACTCCCATCT-3’ 5’-TTCTGCGCACTGAGGAGAGG-3’ 
Cd40l 5’-AGGCGGCAAATACCCACAGT-3’ 5’-TGGCTTGCTTCAGTCACGTTG-3’ 
Ccl21a 5’-GCTCCAAGGGCTGCAAGAGA-3’ 5’-TTGCCTGTGAGTTGGACCGT-3’ 
Cxcl9 5’-TCTGCCATGAAGTCCGCTGT-3’ 5’-GCAGGAGCATCGTGCATTCC-3’ 
Adipoq 5’- AAGGCCGTTCTCTTCACCTA-3’ 5’-TACACCTGGAGCCAGACTTG-3’ 
Pparg 5’-TTCTGCGCACTGAGGAGAGG-3’ 5’-AGACTCTGGGTTCAGCTGGT-3’ 
Ppara 5’-AGACTCTGGGTTCAGCTGGT-3’ 5’-GAAGCTGGAGAGAGGGTGTC-3’ 
Rorα 5’-ACTTGCGGGAAGAGCTCCAG-3’ 5’-CACACAGCTGCCACATCACC-3’ 
 
Note: Primer sets were designed at https://www.genscript.com/tools/real-time-pcr-
taqman-primer-design-tool. The parameters used include the minimum Tm 58oC, 
optimum Tm 59oC, maximum Tm 60oC, primer length 16-20 bp, amplicon size 90-150 
bp. Primer crossing exon junction is not allowed. h=human.  
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3. Supplementary Materials and Methods 
 
The details of other materials and methods used throughout the study include (1) 
Animal treatment; (2) Production of recombinant FGF21; (3) Cell culture; (4) Histology 
analysis; (5) Immunohistochemistry and immunofluorescence; (6) Analysis of FGF21 
levels on human pancreatic tissue array; (7) Pancreatic fibrosis; (8) PanIN 
quantification; (9) Ki-67 proliferation index; (10) Protein isolation and Western blot 
analysis; (11) RAS activity assay; (12) Gene expression analysis; (13) Triglycerides 
content in the pancreas; (14) Pancreatic acini extraction and 3-dimensional culture; (15) 
Serum FGF21 levels; (16) Statistical analysis. 
 
Animal treatment 
fElasCreERT, fElasCreERT;KrasLSL-G12D/+, Ptf1aCreERT;KrasLSL-G12D/+, and fElasCreERT;Trp53LSL-
R172H/+
 mice, including both male and female, were randomly recruited and given TM by 
peritoneal injection for five consecutive days to fully activate Cre recombinase in acinar 
cells. According to the treatment plan, KrasG12D/+ and fElasCreERT mice were fed with 
either normal laboratory supplied diet or high-fat diet (60% fat, Test Diet DIO 58Y1 van 
Heek Series; Lab Supply, Fort Worth, TX). The mice were given rhFGF21 at 0.5 
mg/kg/day as described1, 2. Phosphate-buffered saline (PBS) of the same volume was 
used as an experimental control. Body weight of each mouse was measured at least 
once a week. After about ten weeks of treatment or due to tumor burden requiring a 
humane sacrifice, mice were euthanized, and the pancreas, liver, spleen, blood, and/or 
fat tissues were harvested for further experiments.  
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Production of recombinant FGF21  
Recombinant 6 x His-tagged human FGF21 for in vivo injection was produced in E. coli 
BL21 DE3 and purified as described3.  
 
Cell culture 
Panc-1, MIA Paca-2, SU86.86, and AsPC-1 cells were cultured in RPMI 1640 or DMEM 
media supplemented with 10% FBS, as well as penicillin and streptomycin. All these cell 
lines were obtained from American Type Culture Collection (ATCC) and proven to carry 
oncogenic KRAS. HPDE cells were cultured in serum-free keratinocyte (KSF) medium 
supplemented by epidermal growth factor and bovine pituitary extract (Life 
Technologies, Inc., Grand Island, NY). 
 
Histology analysis 
Mouse tissues were dissected, rinsed with PBS, and fixed in 10% formalin solution 
overnight. Formalin-fixed tissue samples were placed in cassettes, dehydrated in 
alcohol gradients, and then embedded in paraffin for sectioning. The 5-µm-thick tissue 
sections were dewaxed in xylene, rehydrated through reversed ethanol gradients, 
washed in PBS thoroughly, and then stained with H&E. After staining, the pathological 
changes in pancreatic tissues were evaluated by our experienced pathologists based on 
criteria described at http://pathology.jhu.edu/pc/professionals/DuctLesions.php. PDAC 
incidences were also assessed by two independent pathologists. 
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Immunohistochemistry and immunofluorescence 
To evaluate the levels of representative protein makers, including  COX-2, FGF21, KLB, 
F4/80, Ki-67, Cyclin D1, amylase, CD3, and CK19, immunohistochemical and 
immunofluorescent analyses were performed as described4, 5. Briefly, after 
deparaffinized in xylene, rehydrated in alcohol gradients and rinsed with PBS, tissue 
sections were subjected to heat-mediated antigen retrieval with citrate buffer (pH 6.0) 
and then treated with 0.5% H2O2 in methanol for 10 min to remove the endogenous 
peroxidase followed by blocking with normal serum. The treated sections were then 
incubated with primary antibodies against COX-2 (1:20, Thermo), FGF21 (1:200, 
Abcam), KLB (1:200, Abcam), F4/80 (1:100, eBioscience), Ki-67 (1:200, Thermo), 
Cyclin D1 (1:200, Santa Cruz), amylase (1:400, Santa Cruz), and CK19 (1:50, Santa 
Cruz) at 4°C overnight. After washing, the sections  were further incubated with the 
appropriate biotinylated secondary antibodies (Vector Laboratories, CA, USA) at room 
temperature for 1 hr, washed again in PBS, incubated with ABC reagent (Vector 
Laboratories, CA, USA) for 30 min, and then reacted with diaminobenzidine (DAB, 
Vector Laboratories, CA, USA) for about 3 min. The resulting sections were then 
counterstained with hematoxylin until the desired stain intensity developed. 
Immunofluorescence was performed as described4, 5. Fiji ImageJ software was used to 
obtain data from most IHC images for quantification and statistical analyses. 
 
Analysis of FGF21 levels on human pancreatic tissue array  
Human normal (n=45) and PDAC (n=59) pancreatic tissue array samples (US Biomax, 
MD, USA) were processed for IHC analysis on FGF21 expression. Positive FGF21 
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expression was defined as the presence of cytoplasm staining in cells. Tissue cores 
containing tumor foci in less than 10% of the whole area were excluded from evaluation. 
Relative FGF21 levels were scored as the product of a proportion score and an intensity 
score. The proportion score was determined by the fraction of positively stained 
neoplastic cells (0, none; 1, <10%; 2, 10–50%; 3, 51–80%; 4, >80%). The intensity 
score represented the staining intensity (0 = negative, 1 = weak, 2 = moderate, 3 = 
strong). Mean staining intensity of three tumor cores per patient on the tissue array was 
calculated for each case.  
 
Pancreatic fibrosis 
To evaluate pancreatic fibrosis, we analyzed the levels of pancreatic collagen using 
Sirius Red staining on pancreatic tissue sections. Briefly, tissue sections were 
deparaffinized, hydrated in ethanol gradients and distilled water, and then incubated in 
adequate Picro-Sirius Red Solution (Abcam, MA, USA) for 60 minutes. After rinsing 
quickly in two changes of acetic acid solution followed by dehydration with two changes 
of absolute alcohol, the Sirius Red-stained sections were sealed and photographed 
under light microscopes. Three digitized pictures of each pancreatic section were 
photographed using an Olympus iX81 microscope at 200x magnification. The images 
were analyzed using Fiji ImageJ software. Levels of pancreatic collagen deposition 
were presented as the ratio of the mean collage-stained area to the whole mean area of 
the section and finally converted to relative collagen contents. 
 
PanIN quantification 
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The H&E stained pancreatic sections were histologically evaluated by two independent 
pathologists blinded to the experimental groups according to histopathology criteria as 
recommended6. Each lobule of the pancreas on each section was examined, and the 
highest grade lesion from each lobule was identified, and the percentage of lobules with 
the highest grade of each type of lesion was determined based upon the total number of 
lobules counted. 
 
Ki-67 proliferation index 
Ki-67 proliferation index was determined as the percentage of positively stained cell 
nuclei of neoplastic cells. 5-10 random fields were chosen per tissue section (200x). 
Non-neoplastic cells such as lymphocytes and endothelial cells were excluded for 
counting7. 
 
Protein isolation and Western blot analysis 
To evaluate protein levels of amylase, α-SMA, FGF21, KLB, GAPDH, and β-actin, cell 
and tissue lysates were separated by SDS-PAGE and analyzed by immunodetection as 
described8. Briefly, snap-frozen tissues were homogenized in 0.5-1 ml ice-cold lysis 
buffer (Millipore, MA, USA) with protease inhibitor cocktail tablets (Roche, Germany). 
Tissue homogenates were centrifuged at 15,000 g for 15 minutes at 4°C, and the 
supernatant was collected. Protein lysates from tissue were aliquoted to determine 
protein concentration using a protein assay dye reagent concentrate (Bio-Rad, CA, 
USA).  The lysates were separated by SDS-PAGE and then transferred to nitrocellulose 
membranes 8. The membranes were rinsed with PBS containing 0.05% Tween 20 
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(PBS-T) and probed with the following antibodies against amylase (1:20000; Santa Cruz 
Biotechnology Inc.), α-SMA (1:400; Abcam), FGF21 (1:1000; Abcam), KLB (1:2000, 
R&D), GAPDH (1:10,000; Sigma-Aldrich), and β-actin (1:10000, Sigma-Aldrich). The 
membranes were then washed with PBS-T and probed with the respective secondary 
antibodies conjugated to horseradish peroxidase or Alexa-Fluor 800 or 680 for one hour 
at room temperature.  Autoradiography or the Odyssey Imaging System (LiCor 
Biosciences, Lincoln, NE) was used to visualize protein bands. Stripping buffer 
(Thermo, MA, USA) was used for sequential blotting and reprobing with other antibodies 
to provide a loading control. ImageJ densitometry software was used to quantify 
individual bands. 
 
RAS activity assay 
Levels of GTP-occupied RAS from mice pancreatic lysates were measured using a RAF 
pull-down assay kit (Millipore, MA, USA) as previously described9. Briefly, snap-frozen 
pancreatic tissues were homogenized on ice in lysis buffer. Cellular debris was removed 
by centrifuging at 15,000g for 20 minutes at 4°C. P rotein concentrations were 
measured. About 1000 µg of lysates were incubated for 50 minutes at 4°C w ith agarose 
beads coated with RAF-RBD domain, which can specifically pull-down the GTP-bound 
form of Ras proteins. The beads were then washed for 3 times with washing buffer. 
Active RAS was analyzed by immunoblotting with an anti-RAS primary antibody 
(1:2000, Millipore) using GAPDH as a sample loading control. The intensity of the bands 
generated from Western blot assay was quantified using ImageJ software, and the fold 
changes relative to RAS activity from fElasCreERT mice were determined.  
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Gene expression analysis  
The gene expression of Fgf21, Klb, Fgfr1, multiple inflammatory cytokines 
(Inflammatory Cytokines and Receptors PCR Array, Qiagen) and multiple FGF21-
regulating transcription factors relative to β-actin and 18S rRNA (Supplementary Table 
1) were analyzed by qRT-PCR. Total RNA isolation, 1st strand cDNA synthesis, semi-
quantitative PCR, and qPCR were performed as described8. Briefly, tissues or cells 
were homogenized in 1 ml TRIzol Reagent (Ambion, Life Technologies, CA), total RNAs 
were further separated from other cell contents by sequential chloroform and 
isopropanol precipitation. Aliquots of RNA samples were quantified and examined 
before reverse transcription using a Nanodrop to verify that there was no contamination 
with protein and genomic DNA. Semi-quantitative RT-PCR products after 32 cycles 
were analyzed by agarose gel electrophoresis. Inflammatory cytokine gene arrays 
(Inflammatory Cytokines and Receptors PCR Array, Qiagen) were first used to 
determine by qRT-PCR the changes in gene expression of inflammatory 
cytokines/chemokines and receptors. Gene expressions of statistically significant 
alterations were then individually confirmed by qRT-PCR using primer sets as listed in 
Supplementary Table 1, in the Quantifast SYBR Green PCR mix (Qiagen GmbH, 
Germany) with a reaction condition of initial denaturation at 95oC for 5 min and then 40 
cycles of 95oC for 10 seconds and 60oC for 30 seconds in QuantStudio 3 machine. The 
comparative threshold Ct method was used with β-actin and 18S rRNA as internal 
references. Data quantification and statistic analysis were performed in Microsoft Excel 
and GraphPad Prism 6.0.  
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PPARG activation and FGF21 expression 
To evaluate the effect of PPARG activation on pancreatic FGF21 expression, we 
utilized the mutant KRAS-harboring Panc-1 cells. These cells were freshly cultured in 
RPMI-1640 media containing 10% FBS in 6-well plates at equal cell density. When 
reaching subconfluent (about 80%), these cells were treated with Rosiglitazone at 
concentrations of 0, 0.1, 1, and 10 µM for 18 hours. Cells were washed once with warm 
1 x PBS, and total RNA was extracted for qRT-PCR analysis as described above. 
 
Triglycerides content in the pancreas 
Triglyceride colorimetric assay kit (Cayman Chemical Company, MI, USA) was used to 
determine the triglycerides content in the pancreas. 500 mg of fresh pancreatic tissues 
were minced into small pieces and homogenized in 2 ml of diluted Standard Diluent 
containing protease inhibitor cocktail tablets (Roche, Germany). The homogenates were 
then centrifuged at 10,000 x g for 10 minutes at 4°C, and the supernatant was 
transferred to another tube. An appropriate volume of samples was added to the 
designated wells on the plate according to the protocol. Reactions were initiated by 
adding the corresponding diluted enzyme solution. After incubating for 15 minutes at 
room temperature, the absorbance of the reaction was determined at 530-550 nm on a 
plate reader. 
 
Pancreatic acini extraction and 3-dimensional culture 
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Pancreatic acini were prepared as described previously10, seeded in collagen containing 
24-well plates, cultured, treated daily with rhFGF21 (1 µg/ml) or PBS, and stained with 
H&E or co-immunofluorescent probes as described10-12. Three independent 
experiments were performed. 
 
Serum FGF21 levels 
Mouse whole blood samples were collected in clean 1.5 ml Eppendorf centrifuge tubes. 
For rhFGF21 treatment groups, blood samples were collected 24 hrs after rhFGF21 
injection. Tubes with blood samples were placed on ice for 30 min without any 
disturbance. Blood samples were then centrifuged at 3,000 rpm for 10 min at 4°C, and 
the supernatants were harvested and stored at −80°C  until analyzed. Serum FGF21 
concentrations were measured using Rat/Mouse (#MF2100) FGF21 enzyme-linked 
immunosorbent assay (ELISA) kits (Quantikine ELISA; R&D Systems, Minneapolis, MN, 
USA). 
 
Statistical analysis  
Comparison between two groups was analyzed by Student's t-test unless otherwise 
indicated. Log-rank (Mantel-Cox) test, based on the Log-rank statistic, was performed to 
determine the significant differences between two or more survival curves. The body 
weight data were analyzed by two-way ANOVA Tukey’s multiple comparisons test. p 
values of less than 0.05 were considered to be statistically significant. Results were 
expressed as group mean ± SEM or mean ± SD. *, p<0.05; **, p<0.01; ***, p<0.001; 
****, p<0.0001. ns, not significant. We used GraphPad Prism 6.0 for statistical analysis. 
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